Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs
| Autor: | Kurbatova, E. V., Cavanaugh, J. S., Shah, N. S., Wright, A., Kim, H., Metchock, B., Van Deun, A., Barrera, L., Boulahbal, F., Richter, E., Martín-Casabona, N., Arias, F., Zemanova, I., Drobniewski, F., Santos Silva, A., Coulter, C., Lumb, R., Cegielski, J. P. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Drug susceptibility
Bacterial diseases DNA Mutational Analysis Antitubercular Agents Global Microbial Sensitivity Tests Mycobacterium tuberculosis Laboratory network bacterial infections and mycoses Article First-line drugs Drug resistance Drug Resistance Bacterial Tuberculosis Multidrug-Resistant polycyclic compounds Isoniazid Humans Tuberculosis Second-line drugs Rifampin Geographical distribution Rifampicin Molecular diagnostic techniques Retrospective Studies |
| Popis: | Based on data from 14 Supranational Tuberculosis (TB) Reference Laboratories worldwide, the proportion of rifampicin-resistant isolates that were isoniazid-susceptible by phenotypic drug-susceptibility tests varied widely (0.5%–11.6%). Rifampicin-resistant isolates that were isoniazid-susceptible had significantly lower rates of resistance to other first-line and second-line anti-TB drugs (except rifabutin) compared to multidrug-resistant isolates. Rifampicin resistance is not always a good proxy for a presumptive diagnosis of multidrug-resistant tuberculosis, which has implications for use of molecular assays that identify only rifampicin resistance-associated DNA mutations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|